200,000+ products from a single source!
sales@angenechem.com
Home > Other Building Blocks > 413599-62-9
413599-62-9 | ZD-4190
CAS No: 413599-62-9 Catalog No: AG01FPEQ MDL No:
Product Description
Catalog Number:
AG01FPEQ
Chemical Name:
ZD-4190
CAS Number:
413599-62-9
Molecular Formula:
C19H16BrFN6O2
Molecular Weight:
459.2717
IUPAC Name:
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(triazol-1-yl)ethoxy]quinazolin-4-amine
InChI:
InChI=1S/C19H16BrFN6O2/c1-28-17-9-13-16(10-18(17)29-7-6-27-5-4-24-26-27)22-11-23-19(13)25-15-3-2-12(20)8-14(15)21/h2-5,8-11H,6-7H2,1H3,(H,22,23,25)
InChI Key:
YBTGTVGEKMZEQX-UHFFFAOYSA-N
SMILES:
COc1cc2c(ncnc2cc1OCCn1nncc1)Nc1ccc(cc1F)Br
Properties
Complexity:
523
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
458.05g/mol
Formal Charge:
0
Heavy Atom Count:
29
Hydrogen Bond Acceptor Count:
8
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
459.279g/mol
Monoisotopic Mass:
458.05g/mol
Rotatable Bond Count:
7
Topological Polar Surface Area:
87A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.5
Literature
| Title | Journal |
|---|---|
| PET imaging of early response to the tyrosine kinase inhibitor ZD4190. | European journal of nuclear medicine and molecular imaging 20110701 |
| The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues. | British journal of cancer 20090804 |
| Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20090101 |
| Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts. | Molecular cancer therapeutics 20060801 |
| Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. | Magnetic resonance imaging 20031001 |
| Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. | Magnetic resonance imaging 20030601 |
| Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. | Journal of medicinal chemistry 20020314 |
| Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. | Journal of medicinal chemistry 19991230 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.